Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
Status:
Active, not recruiting
Trial end date:
2022-01-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to support the dose selection for future studies by evaluating
efficacy and safety of different QBW251 doses in COPD patients with chronic bronchitis and a
history of exacerbations, compared to placebo, when added to a triple combination therapy of
LABA, LAMA and ICS with respect to trough FEV1 change from baseline after 12 weeks of
treatment.